What are the main indications of Fezonaitan and what situations it is suitable for?

Fezolinetant is a new non-hormonal drug that is a neurokinin 3 receptor antagonist (NK3R antagonist). Its main indication is to relieve common vasomotor symptoms (VMS) in menopausal women, especially moderate to severe hot flashes and night sweats. These symptoms are the most typical symptoms of menopausal women, and when severe, they can affect sleep, emotional stability, and overall quality of life. Different from traditional estrogen replacement therapy, fizonitant blocks neurokinin 3 receptors in the brain related to temperature regulation, acting directly on the hypothalamus to regulate abnormal body temperature control mechanisms from the source, thereby significantly reducing the frequency and intensity of vasomotor symptoms.

In the area of menopausal management, filazonatant provides a new treatment option for women who are unable or unwilling to undergo hormone therapy. Especially for patients with breast cancer risk, history of blood clots, or other contraindications to hormone use, the drug has certain advantages in terms of safety and tolerability due to its non-hormonal nature. In addition, studies have shown that filazonatant may also have a positive effect in some women who have entered artificial menopause due to surgical ovarian failure, especially if they have typical symptoms of VMS.

Currently, the main approved indications for nonazonatant are focused on moderate to severe hot flashes in postmenopausal women, but the possibility of its expansion into other hormone-related symptom areas in the future cannot be ruled out. It should be noted that this drug is not used to treat genitourinary syndrome caused by estrogen deficiency, nor is it used to prevent long-term complications of menopause such as osteoporosis. Before considering the use of fezonatant, patients are advised to undergo detailed symptom assessment and medication consultation to ensure clear indications and exclude potential contraindications.

Reference materials:https://www.veozah.com/